Elite Pharma Reports Positive Bioequivalence for Anticonvulsant, Targeting $840M Market
ELTP is trading near its 52-week low of $0.325 (4.3% above the low) on elevated volume (2.4× avg).
Summary
Elite Pharmaceuticals announced positive results from a pivotal bioequivalence study for an undisclosed generic anticonvulsant drug. This product targets an $840 million market, representing a significant opportunity for the company. The positive results are a critical step towards filing an Abbreviated New Drug Application (ANDA) with the FDA. This news follows the company's recent commercial launch of generic methadone and the filing of an ANDA for a generic anticoagulant, demonstrating consistent progress in expanding its generic product pipeline.
At the time of this announcement, ELTP was trading at $0.34 on OTC in the Life Sciences sector, with a market capitalization of approximately $365.3M. The 52-week trading range was $0.33 to $0.82. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: TMX Newsfile.